^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    MCM10 overexpression

    i
    Other names: MCM10, Minichromosome Maintenance 10 Replication Initiation Factor, Minichromosome Maintenance Complex Component 10, Protein MCM10 Homolog, PRO2249, HsMCM10, CNA43, DNA43, MCM10 Minichromosome Maintenance Deficient 10 (S. Cerevisiae), MCM10 Minichromosome Maintenance Deficient 10, Homolog Of Yeast MCM10
    Entrez ID:
    55388
    over1year
    Multifaceted role of the DNA replication protein MCM10 in maintaining genome stability and its implication in human diseases. (PubMed, Cancer Metastasis Rev)
    This review explores the mechanism associated with MCM10's multifaceted role in DNA replication initiation, chromatin organization, transcriptional silencing, replication stress, fork stability, telomere length maintenance, and DNA damage response. Finally, we discuss the role of MCM10 in the early detection of cancer, its prognostic significance, and its potential use in therapeutics for cancer treatment.
    Review • Journal • BRCA Biomarker
    |
    BRCA2 (Breast cancer 2, early onset) • MCM10 (Minichromosome Maintenance 10 Replication Initiation Factor)
    |
    MCM10 overexpression
    almost3years
    MCM10 as a novel prognostic biomarker and its relevance to immune infiltration in gliomas. (PubMed, Technol Health Care)
    MCM10 is an independent prognostic index of glioma patients, and the high expression of MCM10 suggests a poor prognosis; MCM10 expression is closely related to the immune cell infiltration of gliomas, and MCM10 may be related to drug resistance and development of gliomas.
    Journal
    |
    NCAM1 (Neural cell adhesion molecule 1) • MCM10 (Minichromosome Maintenance 10 Replication Initiation Factor)
    |
    IDH wild-type • MCM10 overexpression
    over3years
    Over-Activation of Minichromosome Maintenance Protein 10 Promotes Genomic Instability in Early Stages of Breast Cancer. (PubMed, Int J Biol Sci)
    Overall, the findings of this study revealed a novel mechanism by which MCM10 promotes genomic instability and breast cancer progression, and effectively differentiates the active degree of breast cancer aggressiveness. Thus, MCM10 has the potential to be a clinically useful biomarker as well as a therapeutic target for future breast cancer treatment.
    Journal
    |
    CDH1 (Cadherin 1) • VIM (Vimentin) • MCM10 (Minichromosome Maintenance 10 Replication Initiation Factor) • RPA2 (Replication Protein A2)
    |
    CDH1 expression • MCM10 overexpression • SRF overexpression
    over4years
    Aberrant MCM10 SUMOylation induces genomic instability mediated by a genetic variant associated with survival of esophageal squamous cell carcinoma. (PubMed, Clin Transl Med)
    These findings not only demonstrate a potential biological mechanism between aberrant SUMOylation, genomic instability and cancer metastasis, but also provide a promising biomarker aiding in stratifying ESCC individuals with different prognosis, as well as a potential therapeutic target MCM10.
    Journal
    |
    MCM10 (Minichromosome Maintenance 10 Replication Initiation Factor)
    |
    MCM10 overexpression • SRF overexpression
    |
    Germanin (suramin)